Heron Therapeutics, Inc.
HRTX
$2.48
$0.093.77%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 13.57% | 12.13% | 15.60% | 16.05% | 17.99% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.57% | 12.13% | 15.60% | 16.05% | 17.99% |
| Cost of Revenue | -44.80% | -47.55% | -41.77% | -32.85% | -36.63% |
| Gross Profit | 231.84% | 388.72% | 8,078.50% | 367.82% | 153.07% |
| SG&A Expenses | -16.14% | -31.56% | -27.00% | -11.02% | 0.90% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -29.19% | -38.68% | -34.01% | -22.26% | -20.54% |
| Operating Income | 87.61% | 92.79% | 78.24% | 53.55% | 45.05% |
| Income Before Tax | 87.72% | 76.64% | 64.77% | 46.36% | 39.26% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 87.72% | 76.64% | 64.77% | 46.36% | 39.26% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 87.72% | 76.64% | 64.77% | 46.36% | 39.26% |
| EBIT | 87.61% | 92.79% | 78.24% | 53.55% | 45.05% |
| EBITDA | 89.97% | 94.93% | 79.88% | 54.67% | 45.83% |
| EPS Basic | 89.72% | 81.09% | 72.34% | 55.14% | 49.53% |
| Normalized Basic EPS | 89.73% | 93.01% | 81.74% | 62.50% | 55.20% |
| EPS Diluted | 89.72% | 81.09% | 72.34% | 55.14% | 49.53% |
| Normalized Diluted EPS | 89.73% | 93.01% | 81.74% | 62.50% | 55.20% |
| Average Basic Shares Outstanding | 13.47% | 21.70% | 28.68% | 26.39% | 24.01% |
| Average Diluted Shares Outstanding | 13.47% | 21.70% | 28.68% | 26.39% | 24.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
